President Trump’s TrumpRx.gov slashes prices for GLP-1 weight-loss and fertility drugs by up to 84%, delivering real relief to American families battered by sky-high healthcare costs.
Story Highlights
- GLP-1 drugs like Ozempic and Wegovy drop to $245/month for Medicare and $350 on TrumpRx, halving prior costs for diabetes and obesity patients.
- Fertility medications see massive cuts, including Gonal-F to $168/pen and Cetrotide to $22.50, saving thousands per IVF cycle for struggling families.
- CMS Medicare Director Chris Klomp credits Trump’s MFN deals with manufacturers for enabling 25% of Americans to finally afford vital prescriptions.
- TrumpRx bypasses big pharma middlemen and PBMs, building on first-term wins like insulin caps to counter globalist pricing excesses.
Trump’s Bold Drug Pricing Victories
CMS Medicare Director Chris Klomp announced on Fox Business that GLP-1 drugs for diabetes and weight loss now cost roughly half their previous prices thanks to President Trump’s initiatives.
Fertility medications followed suit, with savings of thousands per cycle. TrumpRx.gov, launched in 2026, enforces Most-Favored-Nation pricing from deals with Eli Lilly, Novo Nordisk, and EMD Serono.
These agreements tie discounts to Medicare expansions for obesity treatment and IVF access, directly aiding cash-pay patients who skipped 25% of prescriptions due to cost.
Key Deals and Price Drops
In October last year, Trump announced an 84% discount on EMD Serono IVF therapies via TrumpRx, exempting domestic manufacturing from tariffs.
November 2025 brought White House fact sheets detailing GLP-1 pricing at $245/month for Medicare users on Ozempic, Wegovy, Mounjaro, and Zepbound, with TrumpRx consumer rates averaging $350—a 30% cut from $499.
Specific fertility wins include Gonal-F at $168 per pen, Cetrotide at $22.50, down from $316, and Ovidrel at $84, down from $251. These reductions counteract pre-2025 list prices exceeding $1,000 per month for GLP-1s.
Americans paying less as Trump drug pricing push slashes GLP-1, fertility medicine costs, official says https://t.co/9Zt7wC06qp
— FOX Business (@FoxBusiness) April 7, 2026
Reviving First-Term Reforms
TrumpRx revives the president’s first-term MFN rules, struck down in court, alongside insulin caps at $35/month for select diseases.
Biden’s IRA negotiations left GLP-1 prices higher, but Trump’s 2025 deals overrode them. The platform targets pharmacy barriers, bypassing pharmacy benefit managers amid post-2024 election demands for affordability.
Pharma firms gain Medicare volume and tariff exemptions in exchange, prioritizing American patients over foreign price gouging.
By early 2026, TrumpRx listed 54 drugs, 31% of which were generics, with GLP-1 refills capped at 45 days to avoid $699 hikes. Thirteen states now cover GLP-1s for obesity, expanding access for working families.
Impacts on Families and Economy
Affected families see short-term savings of $2,000+ per IVF cycle and 50% off GLP-1s, easing burdens for 1 in 8 infertile couples and millions managing weight or diabetes.
Economic gains include $443-$598 per drug discounts, countering $21,000 full IVF cycles.
Politically, these wins highlight Trump’s contrast to past fiscal mismanagement, as polls rank healthcare affordability top among voter concerns.
In the long term, MFN incentives boost domestic manufacturing and potential Medicaid expansions.
ASRM welcomed fertility inclusions in February 2026 but urged broader IVF insurance. Critics note limitations like insured focus and GoodRx matches for some drugs, yet official prices remain verifiable wins for everyday Americans.
Sources:
Federal Update: Trump Administration Announces Deal to Bring Most-Favored-Nation Pricing for GLP-1s
TrumpRx Discounts Only One Drug While 22 Million Americans See Costs Rise
Trump Wrong on Drug Pricing in State of the Union
TrumpRx Drugs Website Discount
